Assembly Biosciences (ASMB) Assets Average (2011 - 2026)
Assembly Biosciences (ASMB) posted quarterly Assets Average of $246.5 million for Q1 2026, up 126.0% year-over-year from $109.1 million in Q1 2025, and down 0.9% quarter-over-quarter from $248.8 million in Q4 2025.
Assembly Biosciences (ASMB) Assets Average (2011 - 2026) Analysis & Trends
Assembly Biosciences' Assets Average history runs 16 years deep, the most recent figure standing at $246.5 million for Q1 2026.
- In Q1 2026, Assets Average rose 126.0% year-over-year to $246.5 million; the TTM figure through Mar 2026 stood at $246.5 million (up 126.0% YoY), while the FY2025 annual figure was $188.4 million, up 47.18% from the prior year.
- Assets Average for Q1 2026 stood at $246.5 million, down from $248.8 million in the prior quarter.
- The five-year high for Assets Average was $248.8 million in Q4 2025, with the low at $59.1 million in Q3 2023.
- The 5-year median for Assets Average is $111.7 million (2022), against an average of $130.2 million.
- The sharpest annual moves came in 2023 and 2025: Assets Average tumbled 55.39% in 2023, then soared 126.76% in 2025.
- Assembly Biosciences' Assets Average stood at $111.7 million in 2022, then declined by 15.61% to $94.2 million in 2023, then gained by 16.44% to $109.7 million in 2024, then surged by 126.76% to $248.8 million in 2025, then decreased by 0.9% to $246.5 million in 2026.
- Business Quant data shows ASMB's Assets Average at $246.5 million in Q1 2026, $248.8 million in Q4 2025, and $160.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Assembly Biosciences | 670.88 Mn | 350.52 Mn | - | 283.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 283.17 Mn |
| Mar 31, 2026 | 246.55 Mn |
| Dec 31, 2025 | 248.79 Mn |
| Sep 30, 2025 | 160.39 Mn |
| Jun 30, 2025 | 89.90 Mn |
| Mar 31, 2025 | 109.09 Mn |
| Dec 31, 2024 | 109.72 Mn |
| Sep 30, 2024 | 107.79 Mn |
| Jun 30, 2024 | 117.60 Mn |
| Mar 31, 2024 | 128.35 Mn |
| Dec 31, 2023 | 94.23 Mn |
| Sep 30, 2023 | 59.10 Mn |
| Jun 30, 2023 | 74.85 Mn |
| Mar 31, 2023 | 92.46 Mn |
| Dec 31, 2022 | 111.66 Mn |
| Sep 30, 2022 | 132.48 Mn |
| Jun 30, 2022 | 153.09 Mn |
| Mar 31, 2022 | 176.90 Mn |
| Dec 31, 2021 | 220.02 Mn |
| Sep 30, 2021 | 255.55 Mn |